How to verify Epithalon (Epitalon) purity and batch documentation

Epithalon, also written Epitalon or Epithalone, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG) and the one-letter code AEDG; it was synthesised from the amino-acid composition of Epithalamin, a bovine pineal gland extract, and has since been studied in vitro, in vivo and in silico [6]. The same source gives the formal name and the tetrapeptide class, and notes that the compound is chemically distinct from the pineal extract it was modelled on, so the two should not be treated as interchangeable in documentation or in evidence [6][7].

Verification therefore rests on confirming the AEDG sequence and the accompanying batch record rather than on any single certificate, and the mechanistic work that supports the compound centres on telomerase reverse transcriptase (hTERT) upregulation and telomere length [4][5].

Research Studies

Epithalon and telomere length in human cell lines

Epitalon has been reported to increase telomere length in human cell lines through telomerase upregulation or through alternative lengthening of telomeres (ALT) activity [4][5]. The work describes the tetrapeptide as naturally occurring and links its reported anti-aging effects on mammalian cells to induction of telomerase enzyme activity and extension of telomere length [4]. The authors state that quantitative data on the biomolecular pathway leading to telomere length increase, hTERT mRNA expression, telomerase enzyme activity and ALT activation had not been extensive, which is the gap the study addresses [4][5]. A correction to this work is also indexed [3].

Epithalon and hTERT upregulation in preclinical models

Current preclinical evidence suggests that Epitalon may activate telomerase by upregulating human telomerase reverse transcriptase (hTERT), and in aged primates Epitalon has been examined in that context [8]. This is preclinical material; the hTERT and telomerase readouts are the mechanistic endpoints a laboratory would look for when characterising a lot, not clinical outcomes [8].

Epithalon and geroprotective effects in mammalian cells

Epitalon has been studied for geroprotective and neuroendocrine effects attributed to antioxidant, neuroprotective and antimutagenic activity, arising from both specific and nonspecific mechanisms [6]. The same overview notes that the compound has been examined across in vitro, in vivo and in silico methods over roughly 25 years [6]. These findings are reported in mammalian cell and animal systems.

Epithalon and the hallmarks of aging in peptide therapeutics reviews

A narrative review of therapeutic peptides in gerontology frames peptide agents as targeting hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [2]. The review covers mechanisms, clinical applications, evidence base and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus and regulatory databases [2]. Epitalon appears within that broader peptide class rather than as a separately validated clinical agent [2].

Epithalon and delayed wound healing in an in vitro diabetic retinopathy model

In an in vitro model of diabetic retinopathy, the antioxidant tetrapeptide Epitalon was tested for its effect on delayed wound healing [10]. The study situates short peptides, including di-, tri- and tetrapeptides, as having antioxidant, antimicrobial and anti-inflammatory activities, and tests the hypothesis that the tetrapeptide affects healing in that model [10]. This is an in vitro finding and should be recorded as such in any batch or application note.

Epithalon and Epithalamin as distinct preparations

A narrative review of Epitalon and Epithalamin in regenerative and longevity medicine states that although the two are historically related, they are chemically distinct and their evidence should not be considered interchangeable [7]. Epitalon is the synthetic tetrapeptide developed from the amino-acid composition of epithalamin, a pineal-derived polypeptide preparation [7]. For documentation purposes this distinction matters: a certificate referencing Epithalamin does not describe the AEDG tetrapeptide.

Epithalon and peptide signalling pathways in tissue models

Therapeutic peptides are described as acting on pathways including PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, giving them influence over tissue regeneration in orthopaedic and related models [9]. This is a class-level observation about peptide signalling rather than an Epitalon-specific result, and it is included here only to place the compound within the wider peptide literature [9].

Epithalon and senescence-related resistance markers in lymphoma models

In natural killer/T-cell lymphoma, multidrug-resistant models were established using adriamycin, and cellular senescence was confirmed by markers including P16, P21 and senescence-associated β-galactosidase [1]. Proteomic sequencing of plasma from clinical patients and resistant cells identified LCP2 as a key protein, and phosphoproteomics, mass spectrometry and co-immunoprecipitation were used to characterise the interaction [1]. This study concerns LCP2 and chemoresistance rather than Epitalon, and is cited here only as an example of the senescence and resistance marker panel a laboratory may encounter when validating peptide lots in oncology models [1].

Comparing what each evidence type supports

What a batch record should let you check

Because the identity of the material is a four-residue sequence, the batch documentation should allow a laboratory to confirm the AEDG composition and to distinguish it from Epithalamin, which the literature treats as a separate preparation [6][7]. Where a supplier cites telomere or hTERT data, the underlying study should be identified as human cell line, animal or in vitro work, since the indexed evidence for Epitalon in this area is preclinical or cell-based [4][5][8]. Claims that cannot be traced to a named study, model and endpoint should be treated as unverified.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma — https://europepmc.org/article/PMC/PMC13408427
• [2] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
• [3] Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity — https://europepmc.org/article/PMC/PMC12619744
• [4] Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity — https://europepmc.org/article/PMC/PMC12411320
• [5] Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity — https://doi.org/10.21203/rs.3.rs-7066545/v1
• [6] Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties — https://europepmc.org/article/PMC/PMC11943447
• [7] Epitalon and Epithalamin in Regenerative and Longevity Medicine: Mechanisms, Evidence, and Translational Gaps — https://doi.org/10.20944/preprints202609.0801.v1
• [8] From Cellular Aging to Tissue Protection: Epitalon in Regenerative and Longevity Medicine — https://doi.org/10.20944/preprints202607.2123.v1
• [9] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — https://europepmc.org/article/PMC/PMC12753158
• [10] The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy — https://europepmc.org/article/PMC/PMC12356729